Health TrialsbyHealthPanel

Ocular Surface Disease in Glaucoma Patients on Long-Term Therapy

ConditionsGlaucomaOcular Surface DiseaseDry Eye
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssiut University

About this trial

This cross-sectional study aims to determine the prevalence and severity of ocular surface disease among adult patients with glaucoma receiving long-term topical antiglaucoma medications.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

- Age 18 years or older

Diagnosed glaucoma

Currently receiving one or more topical antiglaucoma medications

Duration of topical antiglaucoma treatment ≥6 months

Disqualifiers

- Current use of concomitant topical ocular medication that may affect the ocular surface (e.g., topical cyclosporine)

Previous ocular surgery within the preceding 6 months

History of corneal surgery or significant ocular trauma affecting the ocular surface

Active ocular infection or significant active ocular inflammation

Trial population

Adult patients with diagnosed glaucoma receiving long-term topical antiglaucoma medications at Assiut University Hospital and El Mabarra Hospital.

Trial design

Design model

Case-only

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

55 Participants
are grouped into 1 trial group
Group A: Single cohort: Glaucoma patients on long-term topical therapy

Trial outcomes

Primary outcomes

1

Prevalence of ocular surface disease

Proportion of patients with ocular surface disease defined as an Ocular Surface Disease Index (OSDI) score ≥13.

Time frame
Baseline

Secondary outcomes

1

Proportion of Patients with Mild Ocular Surface Disease Symptoms

Proportion of patients with mild ocular surface disease symptoms defined as OSDI score 13-22.

Time frame
Baseline
2

Proportion of Patients with Moderate Ocular Surface Disease Symptoms

Proportion of patients with moderate ocular surface disease symptoms defined as OSDI score 23-32.

Time frame
Baseline
3

Proportion of Patients with Severe Ocular Surface Disease Symptoms

Proportion of patients with severe ocular surface disease symptoms defined as OSDI score 33-100.

Time frame
Baseline
4

Mean OSDI score

Mean Ocular Surface Disease Index score (range 0-100).

Time frame
Baseline

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: